Evaxion A (EVAX) EBITDA Margin (2024 - 2025)
Evaxion A's (EVAX) quarterly EBITDA Margin came in at 39.94% in Q3 2025, up 9731.0% YoY from 0.41% in Q3 2024, and up 100.34% on a QoQ basis from 11729.73% in Q2 2025.
Evaxion A (EVAX) EBITDA Margin (2024 - 2025) Analysis & Trends
Evaxion A (EVAX) has 2 years of EBITDA Margin data on file, last reported at 39.94% in Q3 2025.
- Quarterly EBITDA Margin rose 9731.0% year-over-year to 39.94% in Q3 2025, while the trailing twelve-month figure through Mar 2026 was 191.88% (up 23945.0% YoY) and the FY2025 annual result came in at 122.66%, up 31789.0% from the prior year.
- EBITDA Margin advanced to 39.94% in Q3 2025, from 11729.73% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 39.94% in Q3 2025 to a low of 11729.73% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 17.93% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.36% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.75% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -35.57% |
| 10 | Evaxion A | 26.86 Mn | 26.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 39.94% |
| Jun 30, 2025 | -11,729.73% |
| Dec 31, 2024 | -3,298.36% |
| Sep 30, 2024 | -57.37% |
| Jun 30, 2024 | -2,974.68% |
| Mar 31, 2024 | -8,619.61% |